{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:39:54Z","timestamp":1791257994429,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00697","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T14:24:05Z","timestamp":1561127045000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials"],"prefix":"10.3389","volume":"10","author":[{"given":"Qingfang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"key":"B2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0161-5890(02)00252-3","article-title":"The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions","volume":"39","author":"Borner","year":"2003","journal-title":"Mol. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","article-title":"Prognostic index for adult patients with acute myeloid leukemia in first relapse","volume":"23","author":"Breems","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell."},{"key":"B5","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy","volume":"131","author":"Coutre","year":"2018","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/S1470-2045(18)30414-5","article-title":"Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Cramer","year":"2018","journal-title":"Lancet Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","article-title":"Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study","volume":"29","author":"de Vos","year":"2018","journal-title":"Ann. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-01-896290","article-title":"Phase 1b study of venetoclax\u2013obinutuzumab in previously untreated and relapsed\/refractory chronic lymphocytic leukemia","author":"Flinn","year":"2019","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM198110153051601","article-title":"Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting","volume":"305","author":"Gralla","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nm.3076","article-title":"Apoptosis therapy: driving cancers down the road to ruin","volume":"19","author":"Green","year":"2013","journal-title":"Nat. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet, 2010"},{"key":"B16","doi-asserted-by":"publisher","first-page":"41498","DOI":"10.18632\/oncotarget.17241","article-title":"Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16078","article-title":"Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy","volume":"8","author":"Inoue-Yamauchi","year":"2017","journal-title":"Nat. Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax\u2013rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/1060028016685803","article-title":"Venetoclax: a first-in-class oral BCL-2 inhibitor for the management of lymphoid malignancies","volume":"51","author":"King","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1158\/1535-7163.MCT-16-0459","article-title":"Vulnerability of small-cell lung cancer to apoptosis induced by the combination of BET bromodomain proteins and BCL2 inhibitors","volume":"16","author":"Lam","year":"2017","journal-title":"Mol. Cancer. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/13543784.2017.1290078","article-title":"Therapeutic inhibition of BCL-2 and related family members","volume":"26","author":"Levy","year":"2017","journal-title":"Expert. Opin. Investig. Drugs."},{"key":"B27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1158\/1078-0432.CCR-17-1606","article-title":"Venetoclax is effective in small-cell lung cancers with high BCL-2 expression","volume":"24","author":"Lochmann","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/2159-8290.CD-18-1151","article-title":"A phase Ib dose-escalation and expansion study of the BCL2 Inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer","volume":"9","author":"Lok","year":"2019","journal-title":"Cancer Discov."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1309\/491W-L1TN-UFQX-T61B","article-title":"Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia","volume":"113","author":"Marschitz","year":"2000","journal-title":"Am. J. Clin. Pathol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/10428194.2017.1361024","article-title":"Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma","volume":"59","author":"Parikh","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"B36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1040-8428(00)00122-0","article-title":"Acute myeloid leukemia in the elderly: biology and therapeutic strategies","volume":"39","author":"Pinto","year":"2001","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3109\/10428199609067578","article-title":"Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome","volume":"10","author":"Robertson","year":"1996","journal-title":"Leukemia"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1182\/blood-2018-05-853564","article-title":"Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia","volume":"132","author":"Rogers","year":"2018","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","article-title":"Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer","volume":"18","author":"Rudin","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"B45","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"key":"B49","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.bbrc.2018.07.027","article-title":"ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma","volume":"503","author":"Wang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1242\/jcs.00754","article-title":"The Bcl-2-regulated apoptotic pathway","volume":"116","author":"Willis","year":"2003","journal-title":"J. Cell Sci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00697\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T14:24:07Z","timestamp":1561127047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00697\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,21]]},"references-count":56,"alternative-id":["10.3389\/fphar.2019.00697"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00697","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,21]]},"article-number":"697"}}